Bounc­ing back, Med­i­ci­No­va makes big gains af­ter tout­ing triglyc­eride da­ta from a tiny study

Shares of Med­i­ci­No­va rock­et­ed up more than 30% this morn­ing af­ter the biotech $MNOV tout­ed the ear­ly end of a small Phase IIa NASH study with pos­i­tive re­sults in cut­ting the lev­el of triglyc­erides.

Ac­cord­ing to in­ves­ti­ga­tors MN-001 (tipelukast) re­duced mean serum triglyc­erides, a pri­ma­ry end­point, from an av­er­age of 260.1 mg/dL be­fore treat­ment to 185.2 mg/dL af­ter eight weeks of treat­ment, de­liv­er­ing a p val­ue of 0.00006.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER